22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. The Company’s technology also allows the levels of cannabinoids to be decreased or increased in the cannabis plant.
In September 2014, 22nd Century’s wholly-owned subsidiary, Botanical Genetics, LLC, entered into a worldwide license agreement with Anandia Laboratories Inc. Under the terms of the agreement, our Company was granted an exclusive sublicense in the United States and a co-exclusive sublicense in the remainder of the world, excluding Canada, to 1 U.S. patent and 20 patent applications relating to four genes in the cannabis plant that are required for the production of cannabinoids, the active ingredient in the cannabis plan. Anandia sublicense continues through the life of the last to expire patent, which is expected to be 2035.
XXII Detailed Quote
|Day's Range:||1.3700 - 1.4000|
|52wk Range:||0.7300 - 1.7100|
XXII Recent Headlines
- 22nd Century Accepted to Present Proprietary Smoking Cessation Product at BIOCHINA Partnering Forum in Zhuhai, China 04/25/2017 01:45 PM[Business Wire] - 22nd Century Group, Inc. , a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that James Vail, the Company’s Director of Business Development, will present the Company’s X-22 smoking cessation aid to high level executives from Chinese and international pharmaceutical companies at the BIOCHINA Partnering Forum in Zhuhai, China on May 31 – June ...
- 22nd Century Group (XXII) Jumps: Stock Adds 6.5% in Session 04/25/2017 12:15 PM
- 22nd Century Will Play Leading Role in Industrial Hemp Industry 04/20/2017 01:45 PM[Business Wire] - 22nd Century Group, Inc. , a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company is building on its newly developed THC-free marijuana.
- World-Renowned Smoking Cessation Scientist, Dr. Michael Cummings, to Present Keynote Address at 22nd Century Annual Shareholder Meeting 04/18/2017 01:06 PM[Business Wire] - 22nd Century Group, Inc. , a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that K. Michael Cummings, PhD, MPH, Professor of Psychiatry and Behavioral Sciences at the Medical University of South Carolina, will present the keynote address at 22nd Century Group’s annual shareholder meeting.
- Can The Uptrend Continue for 22nd Century Group (XXII)? 04/06/2017 01:44 PM